Table 1 Characteristics of the FA participants and healthy controls in our study. Data are presented as mean (range)

Visit number

Visit 1

Visit 2

Visit 3

Visit 4

Visit 1

N

9

9

8

8

9

Female:male

6:3

6:3

5:3

5:3

6:3

Ambulatory:nonambulatory

8:1

8:1

8:0

8:0

9:0

Age (years)

42.54

(24.18–63.32)

42.59

(24.25–63.36)

41.16

(24.50–63.55)

41.80

(24.92–64.16)

44.11

(25.00–66.00)

Disease duration (years)

14.32

(3.93–27.20)

14.37

(3.97–27.24)

13.12

(4.18–27.45)

13.76

(4.85–28.14)

NA

SARA

12.44

(4.00–33.50)

12.22

(5.00–32.50)

10.69

(6.00–16.00)

14.06

(7.50–21.50)

0

(0–0)

SCAFI

−0.74

(−1.69 to 0.16)

−0.67

(−1.63 to 0.08)

−0.60

(−0.96 to 0.16)

−0.70

(−1.07 to −0.09)

1.41

(0.56–2.29)

8 MW

(s)

11.46

(6.20–26.90)

10.64

(5.85–18.35)

10.47

(5.45–15.50)

11.69

(5.95–22.45)

5.55

(3.60–8.00)

9 HPT—dominant hand

(s)

59.42

(30.10–88.60)

52.28

(33.15–71.35)

49.67

(30.55–84.55)

53.00

(34.00–68.00)

19.98

(15.85–23.95)

9 HPT—nondominant hand

(s)

81.07

(34.80–178.20)

60.09

(23.35–103.50)

58.77

(34.20–72.20)

61.55

(39.50–80.85)

23.16

(18.30–28.57)

PATA rate

18.94

(15.50–25.00)

18.56

(13.50–22.00)

18.94

(15.50–23.00)

18.50

(17.00–22.00)

32.56

(25.00–40.00)

FXN mRNA levels (in normalized Ct values)

6.06

(4.94–7.06)

6.55

(4.90–8.43)

6.50

(5.44–7.93)

6.27

(5.41–7.36)

–

Age of onset

(years)

NA

GAA short allele repeats

–

GAA long

allele repeats

–